Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange Detected<div>Updates the page’s revision/version label from <code>v3.5.2</code> to <code>v3.5.3</code>.</div>SummaryDifference0.1%

- Check18 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedNo substantive changes detected in core content; study details, eligibility criteria, and outcome measures appear unchanged.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision updated to v3.5.0, replacing v3.4.3; no study content or user functionality is affected.SummaryDifference0.1%

- Check54 days agoChange Detected- Revision tag updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded a new condition term, Primary peritoneal carcinoma, and a new external resource (Genetic and Rare Diseases Information Center) for patient education. The page update also includes a new Revision (v3.4.2) and removal of the prior funding-notice (v3.4.1).SummaryDifference0.6%

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.